The CAMBRIA-2 Clinical Trial - Wendy Rolls

Опубликовано: 01 Декабрь 2024
на канале: Breast Cancer Trials

184

The CAMBRIA-2 clinical trial aims to find out if giving a new endocrine therapy treatment known as a ‘selective estrogen receptor degrader’ (SERD) is better at stopping cancer from coming back compared with the usual endocrine (hormone) treatments such as letrozole, anastrozole, exemestane or tamoxifen.

CAMBRIA-2 will recruit 5500 patients at approximately 700 sites across 40 countries over 3 and a half years. BCT will recruit approximately 225 patients at 25 Australian and 3 New Zealand sites.

CAMBRIA-2 is open to women and men who have ER-positive, HER2-negative early breast cancer that has an intermediate or high risk of coming back (recurrence).
----------------------------------------------------------------
Breast Cancer Trials is a group of world-leading breast cancer doctors and researchers based in Australia and New Zealand committed to exploring and finding better treatments for people affected by breast cancer through clinical trials research.

Please like this video then visit www.breastcancertrials.org.au to find out more about our current breast cancer clinical trials that may be suitable for you, and ways in which you can help support breast cancer research.

----------------------------------------------------------------

SUBSCRIBE TO OUR YOUTUBE CHANNEL
   / @breastcancertrials

LET'S CONNECT
Email ►[email protected]
Tel 1800 423 444
WWW ► http://www.breastcancertrials.org.au
Linkedin ►   / 5057154
Twitter ►   / bctrialsanz
Facebook ►   / breastcancertrials
Instagram ►   / breastcancertrials